Man Group plc Has $4.74 Million Stock Holdings in Twist Bioscience Co. (NASDAQ:TWST)

Man Group plc reduced its stake in shares of Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 21.3% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 102,021 shares of the company's stock after selling 27,588 shares during the quarter. Man Group plc owned approximately 0.17% of Twist Bioscience worth $4,741,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Van ECK Associates Corp lifted its stake in Twist Bioscience by 56.4% in the fourth quarter. Van ECK Associates Corp now owns 740 shares of the company's stock valued at $34,000 after acquiring an additional 267 shares during the last quarter. Banque Transatlantique SA acquired a new stake in Twist Bioscience in the fourth quarter valued at approximately $43,000. US Bancorp DE lifted its stake in Twist Bioscience by 72.0% in the fourth quarter. US Bancorp DE now owns 1,436 shares of the company's stock valued at $67,000 after acquiring an additional 601 shares during the last quarter. KBC Group NV lifted its stake in Twist Bioscience by 71.4% in the fourth quarter. KBC Group NV now owns 2,942 shares of the company's stock valued at $137,000 after acquiring an additional 1,226 shares during the last quarter. Finally, Blue Trust Inc. lifted its stake in Twist Bioscience by 19.9% in the fourth quarter. Blue Trust Inc. now owns 4,567 shares of the company's stock valued at $206,000 after acquiring an additional 757 shares during the last quarter.

Insiders Place Their Bets

In other Twist Bioscience news, SVP Paula Green sold 918 shares of Twist Bioscience stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $40.91, for a total transaction of $37,555.38. Following the sale, the senior vice president now owns 130,912 shares in the company, valued at $5,355,609.92. The trade was a 0.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Dennis Cho sold 689 shares of Twist Bioscience stock in a transaction on Monday, May 5th. The stock was sold at an average price of $37.65, for a total transaction of $25,940.85. Following the sale, the insider now owns 110,849 shares in the company, valued at $4,173,464.85. This represents a 0.62% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 26,011 shares of company stock worth $951,499 over the last 90 days. Corporate insiders own 3.01% of the company's stock.

Twist Bioscience Stock Performance

TWST stock traded up $1.15 on Tuesday, reaching $29.41. 1,289,530 shares of the company were exchanged, compared to its average volume of 978,712. Twist Bioscience Co. has a 12 month low of $27.12 and a 12 month high of $60.90. The stock's fifty day moving average price is $36.19 and its 200 day moving average price is $42.60. The firm has a market capitalization of $1.76 billion, a PE ratio of -8.70 and a beta of 2.54. The company has a debt-to-equity ratio of 0.03, a current ratio of 4.96 and a quick ratio of 4.62.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last announced its earnings results on Monday, May 5th. The company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.56) by ($0.10). Twist Bioscience had a negative return on equity of 32.69% and a negative net margin of 59.76%. The company had revenue of $92.79 million for the quarter, compared to the consensus estimate of $92.00 million. On average, research analysts anticipate that Twist Bioscience Co. will post -2.12 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have recently commented on TWST. The Goldman Sachs Group dropped their price target on shares of Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. Scotiabank reissued an "outperform" rating on shares of Twist Bioscience in a research report on Tuesday, February 4th. Guggenheim reissued a "buy" rating and issued a $50.00 price target on shares of Twist Bioscience in a research report on Tuesday, May 6th. Barclays dropped their price target on shares of Twist Bioscience from $58.00 to $45.00 and set an "overweight" rating on the stock in a research report on Thursday, April 10th. Finally, Robert W. Baird dropped their price target on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $50.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.